Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;86(4):748-757.
doi: 10.1016/j.jaad.2021.09.019. Epub 2021 Sep 20.

Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States

Joseph F Merola  1 , Haijun Tian  2 , Dhaval Patil  2 , Craig Richardson  3 , Amie Scott  4 , Yen-Hua Chen  4 , Nina Kim  5 , Peter Hur  2 , April W Armstrong  6
Affiliations
Free article

Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States

Joseph F Merola et al. J Am Acad Dermatol. 2022 Apr.
Free article

Abstract

Background: Among patients in the United States with psoriasis (PsO), limited data exist on the incidence and prevalence of psoriatic arthritis (PsA) based on disease severity.

Objective: To assess the incidence, prevalence, and predictors of PsA among patients with PsO stratified by PsO severity using treatment type.

Methods: Incidence of PsA per 100 PsO patient-years (PY) and prevalence were assessed using the Optum electronic health records database. Incidence was assessed from PsO diagnosis and 1 year after PsO diagnosis overall and stratified by mutually exclusive treatment classes as a severity surrogate.

Results: The overall incidence of PsA was 2.9 (95% CI, 2.9-3.0) events per 100 PY. The incidence (95% CI) by severity surrogate was 2.1 (2.1-2.1), 9.9 (9.5-10.4), and 17.6 (16.9-18.3) events per 100 PY for patients with mild, moderate, and severe PsO as determined by receiving nonsystemics, nonbiologic systemic therapy, and biologics, respectively. When excluding patients diagnosed with PsA 1 year after PsO diagnosis, overall incidence was lower (1.7 [95% CI, 1.6-1.7] events per 100 PY), with similar trends for treatment-severity surrogates.

Limitations: Results may not be generalizable to a wider population.

Conclusion: The risk of developing PsA increased with disease severity and was highest in patients with the most severe PsO.

Keywords: incidence; prevalence; psoriasis; psoriatic arthritis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Dr Merola is a consultant and/or investigator for Merck, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Celgene, Sanofi, Regeneron, Arena, Sun Pharmaceuticals, Biogen, Pfizer, EMD Serono, Avotres, and LEO Pharma. Dr Tian and Author Patil are employees of Novartis Pharmaceuticals Corporation. Dr Hur was an employee of Novartis Pharmaceuticals Corporation at the time of this study. Author Richardson is an employee of Novartis Pharma AG. Author Scott was an employee of KMK Consulting, Inc, providing services to Novartis at the time of this study. Author Chen is an employee of KMK Consulting, Inc. Dr Kim was a postdoctoral fellow at the University of Texas at Austin and Baylor Scott and White Health, providing services to Novartis Pharmaceuticals Corporation at the time of this study. Dr Armstrong has served as an investigator or consultant for AbbVie, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly, EPI Health, Janssen, LEO Pharma, Modernizing Medicine, Novartis, Ortho Dermatologics, Regeneron, Sanofi Genzyme, Science 37, and UCB.

Comment in